Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eszopiclone - Sumitomo Pharma America

Next Previous
Drug Profile

Eszopiclone - Sumitomo Pharma America

Alternative Names: Esopiclone; Estorra; Lunesta; Lunivia; S-Zopiclone; SEP-0227018; SEP-190; SEP-225441

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Eisai Co Ltd; Sepracor; Sumitomo Pharma America
  • Class 2 ring heterocyclic compounds; Esters; Hypnosedatives; Piperazines; Pyrazines; Pyridines; Pyrroles; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia
  • No development reported Generalised anxiety disorder; Major depressive disorder

Most Recent Events

  • 30 Apr 2019 The FDA recommends to update the label of eszopiclone (Lunesta®) for Insomnia to include Black Box warning regarding the complex sleep behaviors
  • 31 May 2018 Eisai completes a phase II trial for Insomnia in Japan (PO) (UMIN000024462)
  • 01 Oct 2016 Eisai initiates enrolment in a phase II trial for Insomnia in Japan (PO) (UMIN000024462)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top